Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks offers value investors a better bang for their buck right now?
NVST shares jump 22% after Q4 EPS and revenue beat, with profits up 58% and double-digit segment growth despite gross margin pressure.
SANM, NVST and WDC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 12, 2026.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Envista (NVST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Envista (NVST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Envista (NVST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Envista Holdings Corporation (NVST) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Envista (NVST) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Envista (NVST) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.24 per share a year ago.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.